. 2017 Jan 18;73(5):563–571. doi: 10.1007/s00228-017-2196-4

Table 1.

Patient characteristics, n = 19

ID	Sex	Age	BMI	Symptom onset (years)	Diagnosis (years)	Start LD (years)	Hoehn & Yahr	UPDRS IV	Wearing off^{b, c} (yes/no)	Dyskinesia^{b, d} (yes/no)	Study dose^e LD/CD (mg)	Last blood sample	Last motor function test
A^a	Male	69	22.8	11	10	10	4	8	Yes	Yes	300/75	300	291
B	Female	70	22.4	11	10	10	4	11	Yes	Yes	220/55	300	321
C	Male	64	26.5	10	6	6	3	14	Yes	Yes	345/86.25	180	171
D ^a	Male	66	25.5	17	15	14	3	4	Yes	Yes	410/102. 5	240	261
E ^a	Male	61	22.3	13	11	11	3	5	Yes	Yes	360/90	240	261
F ^a	Female	82	21.5	12	9	9	3	7	Yes	Yes	360/90	240	261
G	Female	73	25.6	17	15	13	3	9	Yes	Yes	155/38.75	210	201
H ^a	Male	79	27.7	6	4	4	3	4	Yes	Yes	370/92.5	240	261
I ^a	Female	76	24.2	23	12	12	3	7	Yes	Yes	250/62.5	300	321
J ^a	Male	61	24.5	7	4	4	2	3	Yes	No	270/67.5	300	321
K ^a	Male	80	24.7	7	5	5	2	2	No	Yes	360/90	360	321
L ^a	Male	74	23.4	8	8	8	4	4	Yes	No	110/27.5	360	321
M ^a	Male	74	30.0	6	5	5	3	2	Yes	No	250/62.5	300	321
N	Male	80	22.5	35	33	33	5	9	Yes	Yes	250/62.5	180	171
O ^a	Male	73	22.2	7	6	6	2	5	Yes	No	180/45	360	321
P ^a	Male	68	28.3	9	9	9	3	9	Yes	Yes	295/73.75	360	321
Q	Male	69	20.0	17	13	13	5	7	Yes	Yes	365/91.25	300	231
R ^a	Female	65	26.3	4	2	2	3	3	Yes	No	180/45	300	321
S ^a	Male	72	28.7	12	7	7	2	5	Yes	No	195/48.75	360	321
MEAN	14/5	71.4	24.7	12.2	9.7	9.5	–	–	–	–	275/68.75	285.8	280.0
SD	–	6.3	2.7	7.3	6.8	6.5	–	–	–	–	86.3/21.6	58.7	51.7

LD levodopa, CD carbidopa

^aIncluded in the PK analyses

^bReported at inclusion

^cBased on wearing-off questionnaire

^dBased on UPDRS IV

^eLevodopa/carbidopa equivalents based on individual morning dose